Last quarter (Q2 2023), Dechra Pharmaceuticals's total revenue was £―, a decrease of ― from the same quarter last year. In Q2, Dechra Pharmaceuticals's net income was £―. See Dechra Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 23	Jun 22	Jun 21	Jun 20	Jun 19
Total Revenue	-	£ 761.50M	£ 681.80M	£ 608.00M	£ 515.10M	£ 481.80M
Cost of Revenue	-	£ 335.20M	£ 297.00M	£ 262.10M	£ 223.50M	£ 208.70M
Gross Profit	-	£ 426.30M	£ 384.80M	£ 345.90M	£ 291.60M	£ 273.10M
Operating Expense	-	£ 350.50M	£ 289.30M	£ 258.90M	£ 232.90M	£ 227.60M
Operating Income	-	£ 75.80M	£ 95.50M	£ 87.00M	£ 58.70M	£ 45.50M
Net Non Operating Interest Income Expense	-	£ -22.90M	£ -400.00K	£ 9.80M	£ -11.40M	£ -10.50M
Other Income Expense	-	£ 22.10M	£ 13.00M	-	-	-
Pretax Income	-	£ -36.10M	£ 77.60M	£ 74.00M	£ 40.90M	£ 27.80M
Tax Provision	-	£ -8.20M	£ 19.40M	£ 18.50M	£ 7.00M	£ -3.10M
Earnings From Equity Interest Net Of Tax	-	£ -900.00K	£ -1.30M	-	-	-
Net Income Common Stockholders	-	£ -27.90M	£ 58.20M	£ 55.50M	£ 33.90M	£ 30.90M
Basic EPS	-	-	-	-	£ 0.33	£ 0.30
Diluted EPS	-	-	-	-	£ 0.33	£ 0.30
Basic Average Shares	-	-	-	-	£ 103.13M	£ 102.50M
Diluted Average Shares	-	-	-	-	£ 103.48M	£ 102.76M
Dividend Per Share	-	-	-	-	£ 0.32	£ 0.28
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	£ 0.93	£ 0.90
Reported Normalized Diluted E P S	-	-	-	-	£ 0.92	£ 0.90
Rent Expense Supplemental	-	-	-	-	-	£ 3.30M
Total Expenses	-	£ 685.70M	-	£ -521.00M	£ 456.40M	£ 436.30M
Net Income From Continuing And Discontinued Operation	-	£ -27.90M	£ 58.20M	£ 55.50M	£ 33.90M	£ 30.90M
Normalized Income	-	£ 25.20M	£ 62.86M	£ 62.94M	£ 41.36M	£ 36.98M
Interest Expense	-	-	-	-	£ 11.50M	£ 10.50M
EBIT	-	£ -13.00M	£ 78.10M	£ 83.80M	£ 52.40M	£ 38.30M
EBITDA	-	£ 5.60M	£ 94.40M	£ 83.80M	£ 122.00M	£ 108.30M

Currency in GBP

Dechra Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing